Page 145 - 《中国药房》2025年13期

amendment 2018[J]. J Urol，2018，200（6）：1264-1272. lines in oncology[J]. J Natl Compr Canc Netw，2023，21
[ 5 ] CHEN Q H. Crosstalk between microtubule stabilizing （10）：1067-1096.
agents and prostate cancer[J]. Cancers （Basel），2023，15 [17] OUDARD S，RATTA R，VOOG E，et al. Biweekly vs. tri‐
（13）：3308. weekly cabazitaxel in older patients with metastatic
[ 6 ] WANG L，KONG B，WANG J Q，et al. A novel targeted castration-resistant prostate cancer：the CABASTY phase
microtubules transformable nanopeptide system yields 3 randomized clinical trial[J]. JAMA Oncol，2023，9（12）：
strong anti-prostate cancer effects by suppressing nuclear 1629-1638.
translocation of androgen receptors[J]. Adv Mater，2024， [18] FIZAZI K，KRAMER G，EYMARD J C，et al. Quality of
36（48）：e2407826. life in patients with metastatic prostate cancer following
[ 7 ] YAKKALA P A，KAMAL A. Dual-targeting inhibitors in‐ treatment with cabazitaxel versus abiraterone or enzaluta‐
volving tubulin for the treatment of cancer[J]. Bioorg mide （CARD）：an analysis of a randomised，multicentre，
Chem，2025，156：108116. open-label，phase 4 study[J]. Lancet Oncol，2020，21（11）：
[ 8 ] ZHANG Y，TANG Y D，TANG X Q，et al. Paclitaxel in‐ 1513-1525.
duces the apoptosis of prostate cancer cells via ROS- [19] HSU J L，LEU W J，HSU L C，et al. Phosphodiesterase
mediated HIF-1α expression[J]. Molecules，2022，27 type 5 inhibitors synergize vincristine in killing castration-
（21）：7183. resistant prostate cancer through amplifying mitotic arrest
[ 9 ] CHEN C S，SMITH E M L，STRINGER K A，et al. Co- signaling[J]. Front Oncol，2020，10：1274.
occurrence and metabolic biomarkers of sensory and mo‐ [20] NASEER F，AHMAD T，KOUSAR K，et al. Formulation
tor subtypes of peripheral neuropathy from paclitaxel[J]. of surface-functionalized hyaluronic acid-coated thiolated
Breast Cancer Res Treat，2022，194（3）：551-560. chitosan nano-formulation for the delivery of vincristine
[10] KENTEPOZIDIS N，SOULTATI A，GIASSAS S，et al. Pa‐ in prostate cancer：a multifunctional targeted drug delivery
clitaxel in combination with carboplatin as salvage treat‐ approach[J]. J Drug Deliv Sci Technol，2022，74：103545.
ment in patients with castration-resistant prostate cancer：a [21] ANJUM S，NASEER F，AHMAD T，et al. Co-delivery of
Hellenic oncology research group multicenter phase Ⅱ oncolytic virus and chemotherapeutic modality：vincris‐
study[J]. Cancer Chemother Pharmacol，2012，70（1）： tine against prostate cancer treatment：a potent viro-
161-168. chemotherapeutic approach[J]. J Med Virol，2024，96（7）：
[11] BYEON S，KIM H，KIM J，et al. Docetaxel rechallenge in e29748.
metastatic castration-resistant prostate cancer：a retrospec‐ [22] DI DESIDERO T，DEROSA L，GALLI L，et al. Clinical，
tive，single-center study[J]. Investig Clin Urol，2020，61 pharmacodynamic and pharmacokinetic results of a pro‐
（6）：588-593. spective phase Ⅱ study on oral metronomic vinorelbine
[12] 郑军，郭文浩，李世健，等. 多西他赛治疗转移性去势抵 and dexamethasone in castration-resistant prostate cancer
抗性前列腺癌患者的剂量选择及预后影响因素分析[J]. patients[J]. Invest New Drugs，2016，34（6）：760-770.
国际泌尿系统杂志，2022，42（4）：599-603. [23] PIATEK C I，RAJA G L，JI L Y，et al. Phase Ⅰ clinical
[13] KWON E D，SHAH P H，et al. Therapeutic sequencing trial of temsirolimus and vinorelbine in advanced solid tu‐
improves outcomes for patients with progressive mCRPC mors[J]. Cancer Chemother Pharmacol，2014，74（6）：
[J]. Prostate，2020，80：1216-1224. 1227-1234.
[14] VALE C L，FISHER D J，GODOLPHIN P J，et al. Which [24] KUREK J，MYSZKOWSKI K，OKULICZ-KOZARYN I，
patients with metastatic hormone-sensitive prostate cancer et al. Cytotoxic，analgesic and anti-inflammatory activity
benefit from docetaxel：a systematic review and meta- of colchicine and its C-10 sulfur containing derivatives[J].
analysis of individual participant data from randomised Sci Rep，2021，11（1）：9034.
trials[J]. Lancet Oncol，2023，24（7）：783-797. [25] HU J X，XU J M，ZHAO J L，et al. Colchicine ameliorates
[15] CEVIK O，ACIDERELI H，TURUT F A，et al. Cabazi‐ short-term abdominal aortic aneurysms by inhibiting the
taxel exhibits more favorable molecular changes com‐ expression of NLRP3 inflammasome components in mice
pared to other taxanes in androgen-independent prostate [J]. Eur J Pharmacol，2024，964：176297.
cancer cells[J]. J Biochem Mol Toxicol，2020，34（9）： [26] YANG J J，SONG D K，LI B Q，et al. Replacing the tropo‐
e22542. lonic methoxyl group of colchicine with methylamino in‐
[16] SCHAEFFER E M，SRINIVAS S，ADRA N，et al. Pros‐ creases tubulin binding affinity with improved therapeutic
tate cancer，version 4.2023，NCCN clinical practice guide‐ index and overcomes paclitaxel cross-resistance[J]. Drug

中国药房 2025年第36卷第13期 China Pharmacy 2025 Vol. 36 No. 13 · 1687 ·